Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical Prostatectomy

Posted by Carolyn A. Salter, MD | Feb 2020

Carolyn A. Salter, MD, presented “Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical Prostatectomy” for the Grand Rounds in Urology audience in February, 2020.

How to cite: Salter, Carolyn A. “Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical Prostatectomy” February, 2020. Accessed Apr 2024. https://grandroundsinurology.com/testosterone-therapy-in-men-with-organ-confined-gleason-6-7-prostate-cancer-after-radical-prostatectomy/

Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical Prostatectomy – Summary:

Carolyn A. Salter, MD, a fellow in male sexual and reproductive medicine at Memorial Sloan Kettering Cancer Center, discusses a retrospective data study she and her team conducted on the effects of testosterone therapy in post-prostatectomy men. She first notes the history of testosterone therapy in men with prostate cancer, observing that the results of older studies resulted in the withholding of testosterone from men with prostate cancer. Dr. Salter then details her study, which examined testosterone-deficient men with organ-confined Gleason 6-7 prostate cancer who had undergone radical prostatectomy and had an undetectable PSA level. The men were monitored 2-4 weeks after testosterone therapy initiation, as well as 3-4 months later to check for improvement. They were then followed-up through 38 months, with the study finding that there was no significant risk of biochemical recurrence in these men.

This post is the first in a curated series of lectures originally presented at the Society of Government Service Urologists 2020 Kimbrough Meeting in Charlotte, North Carolina. Other lectures in this series include:

Microscopic Hematuria Evaluation Stratification: A Machine Learning Approach

About The Author

Carolyn A. Salter, MD

Dr. Carolyn A. Salter, MD, is a current fellow in male sexual and reproductive medicine at Memorial Sloan Kettering Cancer Center in New York, New York. She completed her pre-medical undergraduate training with a degree in Behavioral Biology from Johns Hopkins University in Baltimore, Maryland. It was there that she commissioned into the Army as a Second Lieutenant via the ROTC program. Dr. Salter attended medical school at the Uniformed Services University of the Health Sciences, the military medical school in Bethesda, Maryland. Dr. Salter completed her internship and residency in urology at the Walter Reed National Military Medical Center, also in Bethesda, Maryland. She was awarded the Joint Service Commendation Medal for her achievements during residency. Dr. Salter is currently a Major in the United States Army Medical Corps. Her research and clinical interests include testosterone deficiency, erectile dysfunction, Peyronie’s disease, sexual incontinence, and the sexual effects of obstructive sleep apnea. Dr. Salter is a member of the Alpha Omega Alpha Honor Medical Society, the American Urological Association, the Sexual Medicine Society of North America, and the Society of Government Service Urologists.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat